Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irinotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Irinotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Carcinoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irinotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

    NCT07729605 · start 2026-07-30

    Registered record
    Registry ID
    NCT07729605
    Conditions
    Colorectal Cancer Metastatic; Microsatellite Stable (MSS) Colorectal Cancer (CRC)
    Interventions
    FOLFIRI + bevacizumab + QL1706; FOLFIRI + bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-07-30
    Completion
    2029-07-30
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic; Microsatellite Stable (MSS) Colorectal Cancer (CRC)
    InterventionFOLFIRI + bevacizumab + QL1706; FOLFIRI + bevacizumab
    PhasePhase 3
    Registry statusNot yet recruiting

  • Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma

    NCT07603349 · start 2026-06

    Registered record
    Registry ID
    NCT07603349
    Conditions
    Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
    Interventions
    Alternative Postoperative Treatment Regimen; Original Treatment Regimen; Postoperative Observation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2029-12
    Enrolment
    405

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
    InterventionAlternative Postoperative Treatment Regimen; Original Treatment Regimen; Postoperative Observation
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    NCT07415031 · start 2026-05-06

    Registered record
    Registry ID
    NCT07415031
    Conditions
    Solid Tumors
    Interventions
    Adagrasib; Pembrolizumab; Cetuximab; Pemetrexed; Docetaxel; Irinotecan; Leucovorin; Oxaliplatin; Fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-06
    Completion
    2028-02-16
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionAdagrasib; Pembrolizumab; Cetuximab; Pemetrexed +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

    NCT07150403 · start 2025-12-31

    Registered record
    Registry ID
    NCT07150403
    Conditions
    Metastatic Colorectal Carcinoma (mCRC)
    Interventions
    Oxaliplatin intravenous; 5 FU bolus; Folinic acid; 5 FU continuous; Irinotecan; FRUQUINTINIB; BEVACIZUMAB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-12-31
    Completion
    2028-10-31
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Carcinoma (mCRC)
    InterventionOxaliplatin intravenous; 5 FU bolus; Folinic acid; 5 FU continuous +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

    NCT07061080 · start 2025-12-18

    Registered record
    Registry ID
    NCT07061080
    Conditions
    Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin
    Interventions
    Tarlatamab; standard of care second-line chemotherapy (FOLFIRI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2025-12-18
    Completion
    2026-09-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin
    InterventionTarlatamab; standard of care second-line chemotherapy (FOLFIRI)
    PhasePhase 2
    Registry statusTerminated

  • SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

    NCT07474103 · start 2025-11-30

    Registered record
    Registry ID
    NCT07474103
    Conditions
    Rectal Cancer, Adenocarcinoma
    Interventions
    SCRT; Liposomal Irinotecan; Oxaliplatin; Capecitabine; Sintilimab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-11-30
    Completion
    2028-12-31
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer, Adenocarcinoma
    InterventionSCRT; Liposomal Irinotecan; Oxaliplatin; Capecitabine +1 more
    PhaseNot applicable
    Registry statusRecruiting

  • STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

    NCT07213570 · start 2025-10-16

    Registered record
    Registry ID
    NCT07213570
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    standard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2027-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    Interventionstandard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    PhasePhase 2
    Registry statusRecruiting

  • Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

    NCT07173387 · start 2025-10-01

    Registered record
    Registry ID
    NCT07173387
    Conditions
    Pancreatic Cancer
    Interventions
    NALIRIFOX (liposomal irinotecan-based chemotherapy).; Stereotactic Body Radiation Therapy (SBRT).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-10-01
    Completion
    2028-12-31
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionNALIRIFOX (liposomal irinotecan-based chemotherapy).; Stereotactic Body Radiation Therapy (SBRT).
    PhasePhase 2
    Registry statusActive not recruiting

  • Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

    NCT06751394 · start 2025-01-01

    Registered record
    Registry ID
    NCT06751394
    Conditions
    Recurrent Rectal Cancer
    Interventions
    PD-1 antibody (Toripalimab); Capecitabine; Oxaliplatin; Irinotecan; Radiation; surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2028-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Rectal Cancer
    InterventionPD-1 antibody (Toripalimab); Capecitabine; Oxaliplatin; Irinotecan +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    NCT06750094 · start 2024-12-12

    Registered record
    Registry ID
    NCT06750094
    Conditions
    Colorectal Neoplasms
    Interventions
    Amivantamab; Cetuximab; Bevacizumab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-12-12
    Completion
    2029-04-13
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionAmivantamab; Cetuximab; Bevacizumab; 5-fluorouracil +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

    NCT06700603 · start 2024-11-20

    Registered record
    Registry ID
    NCT06700603
    Conditions
    Pancreatic Cancer
    Interventions
    Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11-20
    Completion
    2026-12-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIrinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
    PhasePhase 2
    Registry statusNot yet recruiting

  • FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

    NCT06733038 · start 2024-11-15

    Registered record
    Registry ID
    NCT06733038
    Conditions
    Colorectal Cancer
    Interventions
    Atezolizumab; Bevacizumab; Irinotecan (CPT-11); Oxaliplatin; Leucovorin; Fluorouracil (5-FU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-15
    Completion
    2029-04-01
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionAtezolizumab; Bevacizumab; Irinotecan (CPT-11); Oxaliplatin +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

    NCT06250972 · start 2024-05-15

    Registered record
    Registry ID
    NCT06250972
    Conditions
    Pancreatic Adenocarcinoma
    Interventions
    Gemcitabine, Nab-paclitaxel, Irinotecan; Intensity-Modulated Radiation Therapy (IMRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-05-15
    Completion
    2028-05-01
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma
    InterventionGemcitabine, Nab-paclitaxel, Irinotecan; Intensity-Modulated Radiation Therapy (IMRT)
    PhasePhase 3
    Registry statusRecruiting

  • Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

    NCT06423937 · start 2024-05

    Registered record
    Registry ID
    NCT06423937
    Conditions
    Colorectal Cancer
    Interventions
    combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-05
    Completion
    2027-07
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventioncombination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
    PhasePhase 2
    Registry statusNot yet recruiting

  • Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

    NCT06099951 · start 2023-11-01

    Registered record
    Registry ID
    NCT06099951
    Conditions
    Colorectal Cancer
    Interventions
    Serplulimab + FOLFOXIRI; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-11-01
    Completion
    2027-09-01
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSerplulimab + FOLFOXIRI; Radiation therapy
    PhasePhase 2
    Registry statusNot yet recruiting